Knowledge Hub

Global Research Report explore the Frontier Pharma Obesity - Identifying and Commercializing First-in-Class Innovation

Press release   •   Sep 02, 2016 03:24 EDT

Obesity is a major growing health concern around the world. In most markets, a person is considered obese if their Body Mass Index (BMI) exceeds 30 kilograms per square meter (kg/m2), calculated by dividing body mass in kilograms by height in meters squared. With the global prevalence continuing to rise, the disease has placed significant burden on healthcare expenditure, as it is also a major risk factor for cardiovascular diseases, diabetes and cancer.

Anti-obesity pharmacotherapy can be used as an adjunct lifestyle modification to improve weight loss in order to significantly reduce obesity-associated health risks in obese patients. However, the use of currently available anti-obesity drugs is largely limited by poor long-term safety and a modest weight loss effect. Despite substantial clinical and regulatory challenges, the early-stage obesity pipeline remains robust, containing a high level of first-in-class innovation that has the potential to be translated into effective and safe weight loss treatments.

View Report At :


  • Historically, the obesity market has suffered from long-term safety concerns and modest efficacy with current treatments, both of which contribute to the low prescription rate and limited widespread use.
  • What are the main safety concerns that lead to significant challenges in gaining drug approval in obesity?
  • Why is sustainable weight loss difficult to achieve, and what is the implication for future drug development?
  • Analysis reveals a high level of innovation and diversity in the pipeline, with 75 first-in-class programs identified to act on 60 unique molecular targets.
  • What is the dominant target family across these first-in-class pipeline products?
  • How well do they align with the underlying signaling pathways governing the central and peripheral regulation of food intake, and energy expenditure?
  • Some first-in-class targets are deemed more likely to be developed into marketable treatments than others, having demonstrated substantial body weight reduction in Preclinical studies and addressing multiple mechanisms underpinning the development of obesity.
  • What is the scientific rationale behind these targets? How are they likely to surpass existing treatment?
  • Apart from body weight change, what other parameters are commonly used to measure the effect of investigational therapies?
  • Deals involving first-in-class obesity products are more likely to be made in earlier stages of development than non-first-in-class deals, supported by industry-wide analysis.
  • What is the dominant molecular target in the obesity deals landscape?

Download Sample copy of this Report at :

Table of Contents

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 3

1.2 List of Figures 3

2 Executive Summary 4

2.1 High Unmet Need Remains in the Obesity Market 4

2.2 Highly Innovative and Diverse Pipeline 4

2.3 Deals Landscape Presents Substantial Investment Opportunities 4

3 The Case for Innovation 5

3.1 Growing Opportunities for Biologic Products 6

3.2 Diversification of Molecular Targets 6

3.3 Innovative First-in-Class Product Developments Remain Attractive 6

3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 7

3.5 Sustained Innovation 7

3.6 GBI Research Report Guidance 8

4 Clinical and Commercial Landscape 9

4.1 Disease Overview 9

4.2 Disease Etiology 9

4.2.1 Genetics 9

4.3 Disease Pathophysiology 10

4.3.1 Central Regulation of Energy Homeostasis 10

4.3.2 Endocrine Regulation in Energy Balance 11

4.3.3 Adipose Tissue and Regulation of Energy Expenditure 11

4.3.4 Dysregulation of Adipokines and Contribution to Obesity and Related Metabolic Disorders 12

4.4 Epidemiology 13

4.5 Classification and Diagnosis 13

4.6 Co-morbidities 14

4.6.1 Type 2 Diabetes 14

4.6.2 Hypertension 14

4.6.3 Dyslipidemia and Cardiovascular Diseases 14

4.6.4 Respiratory Complications 14

4.6.5 Osteoarthritis 14 is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.